Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.45 |
| ▸ | CDK4 | P11802 | 3/20 | 0.45 |
| ▸ | CCND1 | P24385 | 3/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.45 |
| ▸ | CAMK2B | Q13554 | 3/20 | 0.45 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.45 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.45 |
| ▸ | CAMK2A | Q9UQM7 | 3/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.45 |
| ▸ | PRKACA | P17612 | 2/20 | 0.45 |
| ▸ | PRKACG | P22612 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL123875 | 0.81 | BTK (0.45) | JAK2BTKCDK2 | |
| Bromide SCHEMBL145644 | 0.80 | BTK (0.44) | JAK2BTKCDK2 | |
| SCHEMBL123552 | 0.79 | JAK2 (0.45) | JAK2BTKCDK2DYRK1A | |
| SCHEMBL29755092 | 0.78 | CDK4 (0.51) | ALDH1A1CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL28770596 | 0.78 | CDK4 (0.51) | ALDH1A1CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL148600 | 0.78 | BTK (0.43) | JAK2BTKCDK2 | |
| SCHEMBL149527 | 0.78 | BTK (0.47) | JAK2BTKALDH1A1CDK4CCND1 | |
| SCHEMBL148464 | 0.78 | BTK (0.43) | JAK2BTKALDH1A1CDK4CCND1 | |
| SCHEMBL19279114 | 0.77 | BTK (0.54) | BTK | |
| SCHEMBL19279567 | 0.77 | BTK (0.53) | PIM1PIM3JAK2BTKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391602-B1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| CN-102325753-A | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2012-01-18 | — | — | CN | disclosed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | PIM1 90/4885PIM3 102/4885JAK2 13/4885 |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | PIM1 90/4885PIM3 102/4885JAK2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.